Influenza virus represents a major public health concern worldwide after recent pandemics. To aid the understanding and characterization of the virus in ever-increasing sample numbers, new research techniques have been used, such as next-generation sequencing (NGS). The current article review used Ovid MEDLINE and PubMed databases to conduct keyword searches and investigate the extent to which published NGS high-throughput approaches have been implemented to influenza virus research in the last 5 years, during which the increase in research funding for influenza studies has been coincidental with a significant per-base cost reduction of sequencing. Through the current literature review, it is evident that over the last 5 years, NGS techniques have been indeed applied to biological and clinical samples at increasing rates following a wide variety of approaches. The rate of adoption is slower than anticipated by most published studies, with three obstacles identified consistently by authors. These are the lack of suitable downstream analytical capacity, the absence of established quality control comparators, and the higher cost to comparable existing techniques.
Introduction
Influenza viruses are well-characterized members of the Orthomyxoviridae family. Genomic subpopulation diversity and new viral mutants emerge constantly because of the continued viral genetic variation and antigenic modification in response to many factors such as host immunity, ecological and environmental factors, resulting in occasional pandemics and annual epidemics (Zhirnov et al. 2009 ). Influenza remains a major threat on the global agricultural and health care systems because of its continued potential to cause pandemics worldwide and because of the increasing number of seasonal infections impacting human and economic health (Fischer et al. 2015) . The high number of infections and the recurrent seasonality mean that influenza is suitable for a number of high-throughput molecular approaches in addition to the basic virological techniques and clinical expertise to strengthen global pandemic preparedness. In addition, the total and proportional funding for influenza research (£39,139,703, 4 .3% of total infection research) increased in 2011e13 compared with 1997e2010 (£126,643,152, 3 .4% of all infection research), hence the field is more likely able to afford the use of new and perhaps more expensive technologies than studies of other infectious diseases (Head et al. 2016) . Coincidentally, the per-base cost of sequencing in the same period has reduced by 92% from 0.52 to 0.04 USD per DNA Mb (National Human Genome Research Institute, January 2010eJanuary 2015 . Hence, according to our working hypothesis, we expected to notice a steady increase in published implementation examples as overall implementation costs were reducing. In this brief report, we review the application of high-throughput next-generation sequencing (NGS) in the study of influenza and present the opportunities and challenges of implementation as reported by the research community.
Currently, there are two major technologies used for influenza genomic sequencing; the NGS and traditional Sanger sequencing (Deng et al. 2015) . The Sanger sequencing technology referred to as first generation has been used for almost four decades and continues to be the standard reference method used. However, there is a gradual yet notable shift away from this technique and in favor of the use of newer technologies, namely the high-throughput NGS (International Human Genome Consortium 2004) . NGS also referred to as deep sequencing or parallel sequencing (massively parallel sequencing) provides high-speed multiplexing capabilities for high-throughput sample sequencing and enormous data volumes of sequencing reads in one run (Barzon et al. 2011) . Along with the decreasing NGS costs, the applications of NGS techniques within routine diagnostic settings are still evolving because of recent and iterative developments in genome sequencing and bioinformatics analyses (Fischer et al. 2015) .
A Number of choices and challenges for NGS platforms
The common process of most NGS technologies is the initial random fragmentation of templates, followed by an amplification process using polymerase chain reaction target-specific primers, resulting in many DNA copies that can be independently sequenced (Metzker 2010) . High-throughput sequencing platforms can be divided into two broad groups depending on the template used. The earliest platforms depend on the production of libraries of clonally amplified templates. The recent arrival of single-molecule sequencing platforms determines the sequence of single molecules without amplification. Within these broad categories, there is considerable variation in performancedincluding in throughput, read length, and error ratedas well as in factors affecting usability, such as cost and run time (Loman et al. 2012) .
NGS technologies have a unique potential for the de novo sequencing of large genomes, genomic markers screening, transcriptome analysis, and several other applications (Bainbridge et al. 2006; Cheval et al. 2011; Greninger et al. 2010; Kuroda et al. 2010; Nakamura et al. 2009; Pettersson et al. 2008; Satkoski et al. 2008; Torres et al. 2008; Wheeler et al. 2008) . However, the complexity and large size of the sequencing data constitute one of the main bioinformatics challenges of NGS data interpretation (Nowrousian 2010) . The primary approach to NGS data analysis can be accomplished by using either one of three main types of tools, such as general-purpose aligners, de novo assemblers, and short-read aligners . NGS methods confer advantages over other techniques such as highly specific reverse transcription-polymerase chain reaction or less-sensitive traditional virological methods for being able to produce unbiased sequencing without prior knowledge of the presence or type of viral agents. This in turn can potentially constitute them into the future gold standard tool for viral genome discovery, especially in the case of recombinogenic viruses, such as influenza (Bialasiewicz et al. 2014) .
Through the current literature review, it is evident that over the last 5 years, NGS techniques have been indeed applied to clinical samples at increasing rates with some studies concentrating on the detection of novel pathogens or pathogens at low detection levels. Several variant strains and viruses have been successfully identified, such as the PIV4 subtype in late 2013(Alquezar-Planas et al. 2013), although it has to be noted that the numbers of unsuccessful attempts are generally not mentioned, unclear, and/or very difficult to even hazard a guess at. Other studies followed the seasonal influenza infections in large population cohorts ), whereas influenza studies on animals have also used NGS capabilities, such as sequences generated from lung tissues of ferrets experimentally infected with influenza A/California/07/2009 (H1N1) . However, the overall numbers of samples used per study vary widely, and the full implementation of a high-throughput analytical pipeline remains difficult to achieve. The implementation challenges, solutions, and expectations of the authors are also summarized.
Methods
Our research based on the Ovid MEDLINE database and the NCBI PubMed databases was conducted with a total of 18 different keywords in different combinations each time (initial concept terms used: Influenza, next generation sequencing, and data not shown). The literature search provided a wide variety of peerreviewed publications ranging in number from (10e18013). The relevant article abstracts were manually selected corresponding to publications where NGS was actually implemented as opposed to being alluded to for future implementation. Then the exact sequencing techniques used were determined, e.g. Illumina (Yu et al. 2014; Jonges et al. 2014; Kampmann et al. 2011; Peng et al. 2014; Karlsson et al. 2013; Sikora et al. 2014; Ren et al. 2013) , two on plasmid-derived material (Depew et al. 2013; Wu et al. 2014) , and 10 reviewed technical and bioinformatics aspects (Barzon et al. 2011; Metzker 2010; Quiñones-Mateu et al. 2014; Park et al. 2013; Dugan et al. 2012; MacLean et al. 2009; Radford et al. 2012; Ansorge 2009; Shendure and Ji 2008; Tsai and Chen 2011) . The number of samples used per study varied widely, with most studies reporting numbers in the low hundreds and less than 10 reporting the use of more than 1000 samples.
Challenges, opportunities, and solutions of NGS implementation
From the aforementioned, it becomes immediately obvious that the initial NGS applications in the field of influenza research are not reflective of a consistent, universally applied, and true highthroughput approach. Indeed, the picture obtained throughout is one reflecting the initial stages for the adoption of a technical innovation. The challenges mentioned by the various authors are summarized in the Table. The generation of high volumes of data requiring sophisticated downstream bioinformatics analyses is mentioned as the primary challenge for the adoption of the method and interpretation of the NGS outputs. In fact, this single challenge is mentioned in more than two-thirds of all the identified studies. The lack of large-scale validation of NGS outputs with regard to costs and data complexity is challenging and perhaps not feasible for individual research groups to achieve, hence its function as an adoptive impediment. The availability of NGS equipment is a second most popular challenge, followed by the high cost of the new technique compared with existing traditional methods.
The solutions suggested to overcome these issues were much more diverse and fragmented in nature. A large number of authors stressed the need for the development of an automated assembly and development software pipeline, making the whole NGS downstream analyses more efficient and reliable. Although most authors appreciate the production of a series of standard operating procedures, very few are willing to test (individually or institutionally) and compare the different recommended standard operating procedures. The ability to match and multiplex the samples in single sequencing runs is one of the solutions implemented to create cost efficiencies according to the manufacturers' recommendations.
The opportunities that NGS provides to research are evident to all authors. The ability to produce a number of complete influenza genomes in a single run at high resolution and the potential to detect heterogeneous populations in a single application are clearly outlined. The production of considerably larger amounts of sequence information in a short time frame and high speed as compared with traditional molecular methods was also welcome.
Discussion
In the last few years, high-throughput NGS technologies have become more widely available, and they are under continuous improvement and development. NGS has already been used in several projects, in metagenomics, whole genome sequencing, RNA sequencing, and small RNA discovery (Barzon et al. 2011) . These technologies confer advantages over older methods, including single-molecule sequencing, high-throughput and increased quantity of sequencing data, while avoiding the necessity for cloning individual DNA fragments (Ansorge 2009 ).
However, NGS technologies share common features that still limit their use. Through the current search, these have been identified as being the generation of high-throughput data that require substantial computational resources for their subsequent analyses and quality control, the high comparative cost of sequencing using NGS, and the availability of suitable equipment (Deng et al. 2015; Metzker 2010) . As such, the complete replacement of the Sanger-based methods is yet unlikely, until the aforementioned barriers are addressed successfully. The NGS cost per run and the cost per sample has already decreased substantially, and higher multiplexing approaches exert further pressure toward this direction .
According to our current observations, the adoption of NGS sequencing in influenza research seems to correlate well with Buxton's law, where "it is always too early [for rigorous evaluation] until, unfortunately, it's suddenly too late (Buxton and Drummond 1987) ." The initial adopters of NGS are unable or reluctant to apply formative assessment of the different existing technologies, in part because the technologies themselves are still under development. However, as the clinical introduction of NGS starts to materialize, the number of NGS adopters increases and the technique becomes more familiar and integrated within organized facilities, and the completion of an evidence-based assessment will be even more difficult to materialize.
In practice, the current NGS applications are very similar to most newly implemented innovations, composed of a hard core of fixed techniques (e.g. library preparation) with a soft periphery of features (e.g. bioinformatics analyses). The existence of this soft periphery means that the distribution of risk and benefits for the adopters is not entirely fixed as NGS can be implemented in a variety of ways that are not fully clarified by the existing peerreviewed literature (Ilinca et al. 2012) . The uncertainty surrounding some of the implementations and outputs would be expected to still generate a multitude of different claims and adoption pathways.
Having said that, NGS is a very successful platform for viral research studies as it has already led to the discovery of novel viruses and their association of pathogenesis in diseases (Quiñones- NGS ¼ next-generation sequencing
Next generation sequencing and influenza virus . Hence, it is widely expected that these technologies will be applied in routine clinical virology laboratories for nearly all viral pathogens including influenza viruses in the not-sodistant future (Gibson et al. 2014; Swenson et al. 2011; Kagan et al. 2012) .
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